#1 Clinical Trials Search in Europe

Dexamethasone

This article explores the use of dexamethasone, a potent corticosteroid, in various clinical trials. Dexamethasone has been studied for its potential benefits in treating a wide range of medical conditions, from eye disorders to severe influenza. We’ll examine how researchers are investigating its efficacy, safety, and optimal dosing strategies across different medical fields.

Table of Contents

What is Dexamethasone?

Dexamethasone is a type of medication known as a corticosteroid or glucocorticoid. It is a synthetic version of hormones naturally produced by the adrenal glands. Dexamethasone is known for its potent anti-inflammatory and immunosuppressive properties, making it useful in treating a wide range of medical conditions[1].

Medical Uses of Dexamethasone

Dexamethasone is used to treat various medical conditions, including:

  • Acute disc herniation-induced sciatica: Dexamethasone can help reduce inflammation and pain associated with this condition[1].
  • Multiple Myeloma: This is a type of blood cancer where dexamethasone is often used in combination with other drugs for treatment[2].
  • COVID-19: Dexamethasone has shown effectiveness in reducing mortality in patients with severe COVID-19 requiring oxygen therapy[3].
  • Asthma in children: It can be used to manage acute exacerbations (sudden worsening) of asthma[4].
  • Prevention of postoperative nausea and vomiting: Dexamethasone is effective in reducing these common side effects after surgery[5].
  • Brain tumors: It can help reduce swelling and symptoms associated with brain tumors in patients undergoing radiation therapy[6].

How is Dexamethasone Administered?

Dexamethasone can be administered in several ways, depending on the condition being treated and the patient’s needs:

  • Intravenous (IV): Given directly into a vein, often used in hospital settings[1].
  • Oral: Taken by mouth as tablets or liquid[4].
  • Subcutaneous: Injected under the skin[5].

The dosage and frequency of administration can vary greatly depending on the condition being treated and the individual patient’s response. Always follow your doctor’s instructions carefully when taking dexamethasone.

Effectiveness of Dexamethasone

Dexamethasone has shown effectiveness in various medical conditions:

  • In acute disc herniation-induced sciatica, intravenous dexamethasone can help reduce pain and inflammation[1].
  • For COVID-19 patients requiring oxygen therapy, dexamethasone has been shown to reduce mortality[3].
  • In children with asthma exacerbations, dexamethasone can be as effective as other corticosteroids like prednisolone[4].
  • For preventing postoperative nausea and vomiting, dexamethasone has shown significant effectiveness, especially when combined with other anti-nausea medications[5].

Potential Side Effects

While dexamethasone can be very effective, it may also cause side effects. Some potential side effects include:

  • Increased blood sugar levels (which can be a concern for people with diabetes)
  • Mood changes or irritability
  • Increased appetite and weight gain
  • Difficulty sleeping
  • Weakened immune system, potentially increasing the risk of infections

Long-term use of dexamethasone may lead to more serious side effects, such as osteoporosis (weakening of bones), cataracts, or adrenal suppression. Always discuss potential side effects with your healthcare provider[6].

Ongoing Research and Clinical Trials

Researchers continue to study dexamethasone to understand its full potential and optimize its use in various conditions:

  • A study is comparing the effectiveness of dexamethasone to prednisolone in treating COVID-19 patients requiring oxygen therapy[3].
  • Another trial is evaluating the use of low-dose versus standard-dose dexamethasone for symptom control in children undergoing radiation therapy for brain tumors[6].
  • Researchers are also investigating the optimal dosing of dexamethasone for preventing postoperative nausea and vomiting[5].

These ongoing studies aim to refine the use of dexamethasone, potentially leading to more effective treatments with fewer side effects for patients in the future.

Condition Dexamethasone Formulation Key Findings/Objectives
Severe Influenza Oral tablets (6 mg daily for 7 days) Evaluating efficacy in reducing hospitalization and improving clinical outcomes
Retinal Vein Occlusion Intravitreal implant (0.7 mg) Assessing changes in macular function and central foveal thickness
Post-extubation Airway Obstruction Intravenous (5 mg or 10 mg every 6 hours) Comparing high vs. low dose in preventing airway obstruction
Ocular Inflammation (post-surgery) DEXTENZA ophthalmic insert (0.4 mg) Measuring intraocular dexamethasone levels and post-operative pain

FAQ

  • What is dexamethasone and how does it work? Dexamethasone is a potent corticosteroid medication that reduces inflammation and suppresses the immune system. It works by mimicking the effects of natural hormones produced by the adrenal glands, helping to control various inflammatory and immune responses in the body.
  • In which medical conditions is dexamethasone being studied? Based on the clinical trials data, dexamethasone is being studied in various conditions including severe influenza, retinal vein occlusion, macular edema, post-extubation airway obstruction, and ocular inflammation following eye surgery.
  • How is dexamethasone administered in these trials? Dexamethasone is administered in different ways depending on the condition being treated. In the trials mentioned, it's given as oral tablets, intravenous injections, intravitreal implants, and even as an ophthalmic insert placed in the tear duct.
  • What are some potential side effects of dexamethasone? Some potential side effects of dexamethasone mentioned in the trials include increased intraocular pressure, reduced visual acuity, corneal edema, and eye pain when used for ocular conditions. Systemic use may lead to metabolic effects like hyperglycemia.
  • How long do the effects of dexamethasone last? The duration of dexamethasone's effects varies depending on the formulation and route of administration. For example, the DEXTENZA ophthalmic insert releases dexamethasone for up to 30 days, while other formulations may have shorter durations of action.

Ongoing Clinical Trials on Dexamethasone

  • Study on the Effectiveness and Safety of Cytarabine, Tafasitamab, and Lenalidomide for Patients with Relapsed Diffuse Large B-Cell Lymphoma

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Study of Ciltacabtagene Autoleucel and Drug Combination for Treatment of High-Risk Smoldering Multiple Myeloma

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of ixazomib, iberdomide and dexamethasone combination in elderly patients with first relapse of multiple myeloma

    Not yet recruiting

    2 1 1
    Investigated drugs:
    France

  • Study on Multiple Myeloma Treatment with Isatuximab, Lenalidomide, and Carfilzomib for Patients Under 66 Eligible for Stem Cell Transplant

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France

  • Study of NTLA-2001 for Patients with Transthyretin Amyloidosis and Heart Disease

    Not yet recruiting

    3 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +8

  • Study on the Effectiveness and Safety of Odronextamab Compared to Standard Treatment in Adults with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Germany Hungary Italy +4

  • Study on Alnuctamab and Mezigdomide for Patients with Relapsed or Refractory Multiple Myeloma

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    Denmark

  • Study on Dexmedetomidine and Ropivacaine for Pain Relief in Shoulder Surgery Patients

    Not yet recruiting

    3 1 1
    Investigated drugs:
    Belgium

  • Study on Daratumumab, Carfilzomib, Pomalidomide, and Dexamethasone for Patients with Multiple Myeloma and Acute Kidney Failure

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    Austria

  • Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia France Germany +6

Glossary

  • Corticosteroid: A class of steroid hormones produced in the adrenal cortex or made synthetically. They have various metabolic functions and are used to treat inflammation.
  • Intravitreal: Referring to the space within the eye, specifically the area behind the lens and in front of the retina.
  • Macular edema: Swelling or thickening of the macula, the central part of the retina responsible for sharp, detailed vision.
  • Retinal vein occlusion: A blockage of the small veins that carry blood away from the retina, potentially leading to vision problems.
  • Dexamethasone implant: A small device inserted into the eye that slowly releases dexamethasone to treat various eye conditions.
  • Microperimetry: A technique used to measure visual function and sensitivity in specific areas of the retina.
  • Multifocal ERG: A diagnostic test that measures electrical responses from multiple areas of the retina simultaneously.
  • Cuff leak volume (CLV): The amount of air that leaks around the endotracheal tube when its cuff is deflated, used to predict post-extubation stridor.
  • Post-extubation stridor: A high-pitched sound during breathing that occurs after removal of a breathing tube, indicating airway narrowing.
  • DEXTENZA: A dexamethasone ophthalmic insert that delivers medication to the eye surface for up to 30 days.

References

  1. https://clinicaltrials.gov/study/NCT00516009
  2. https://clinicaltrials.gov/study/NCT02586038
  3. https://clinicaltrials.gov/study/NCT04765371
  4. https://clinicaltrials.gov/study/NCT05850143
  5. https://clinicaltrials.gov/study/NCT02386059
  6. https://clinicaltrials.gov/study/NCT01135550